USPTO Examiner BECKHARDT LYNDSEY MARIE - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17041657LICE ELIMINATORJanuary 2021August 2024Abandon4711YesNo
17118824ENTERIC COATED TABLETDecember 2020December 2023Abandon3621YesNo
17055046BONE REGENERATION IN COMPROMISED WOUNDSNovember 2020June 2025Allow5521YesNo
17093214COMPOSITIONS I - I AND PRODUCTS AND USES THEREOFNovember 2020December 2023Allow3721YesNo
17050063IMPLANTABLE DEVICE COMPRISING A TEXTILE COMPONENT COMPRISING MULTIFILAMENT YARNS AND/OR SPUN YARNS MADE OF FIBERS COMPLETELY OR PARTIALLY COATED IN CYCLODEXTRIN POLYMEROctober 2020June 2025Abandon5641YesNo
17070914ANTI-INFECTIVE ANTIMICROBIAL-CONTAINING BIOMATERIALSOctober 2020July 2023Abandon6021NoNo
17047304STIFF AND STRONG HYDROGELS, PRODUCTION METHOD AND USES THEREOFOctober 2020March 2024Allow4131YesNo
17039531TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGSSeptember 2020August 2022Allow2311YesNo
17043255OPHTHALMIC DRUG SUSTAINED RELEASE FORMULATION AND USES FOR DRY EYE SYNDROME TREATMENTSeptember 2020November 2022Abandon2511NoNo
16979638PROCESS FOR CONDITIONING OF KERATIN FIBERSSeptember 2020November 2024Abandon5021NoNo
16965434FILMS AND COMPOSITES AND METHODS OF PRODUCTION AND USEJuly 2020November 2023Abandon3931NoNo
16938198Pre-Mixed, Ready-To-Use Pharmaceutical CompositionsJuly 2020September 2022Allow2520YesNo
16963543Patch Containing Nonylic Acid VanillylamideJuly 2020April 2022Allow2110YesNo
16963043COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTSJuly 2020October 2023Allow3931YesNo
16962477TISSUE-ADAPTIVE MATERIALSJuly 2020June 2023Abandon3521NoNo
16947002TOPICAL SUNSCREENJuly 2020February 2025Allow5551NoNo
16913533POROUS SILICA MATERIAL FOR USE AS A PHARMACEUTICAL OR DIETARY ACTIVE INGREDIENTJune 2020August 2024Allow4941YesNo
16957029DRUG-LOADED IMPLANTED MEDICAL DEVICE AND PREPARATION METHOD THEREFORJune 2020October 2023Abandon4031NoNo
16768103PREVENTION OF THE OXIDATION OF PERFUMERY RAW MATERIALSMay 2020May 2024Abandon4741NoNo
16763493INSECT REPELLENT COMPOSITIONS AND METHODS OF USEMay 2020April 2022Abandon2311NoNo
16763434APPLICATION OF PHARMACEUTICAL COMPOSITION IN REGULATION OF FIBROBLAST GROWTHMay 2020February 2025Abandon5861NoNo
16839353METHOD FOR PROVIDING CONTRACEPTIONApril 2020April 2022Abandon2530NoNo
16649153Vanadyl and vanadate for use in reducing stress-induced metabolic derangementMarch 2020February 2023Abandon3531NoNo
16821233Anti-Blue Light Dermal Topical Composition and Applications ThereofMarch 2020November 2021Abandon2011NoNo
16816362Topical Phospholipid Formulations and Methods for Preparing the SameMarch 2020January 2024Abandon4641NoNo
16646113TOPICAL COMPOSITIONSMarch 2020May 2023Abandon3831NoNo
16794988DIETARY SUPPLEMENTATION WITH MIXED ALKALI SALTSFebruary 2020October 2021Allow2021YesNo
16782628Systems and Methods for Preservative Removal from Ophthalmic Formulations Comprising Complexing AgentsFebruary 2020February 2024Abandon4821NoNo
16635243ANTIMICROBIAL COATING MATERIAL COMPRISING NANOCRYSTALLINE CELLULOSE AND MAGNESIUM OXIDE AND METHOD OF PREPARATION THEREOFJanuary 2020March 2022Abandon2621NoNo
16744832AQUEOUS COSMETIC COMPOSITION COMPRISING ALKYLCELLULOSEJanuary 2020February 2024Abandon4931NoYes
16726813NANO-OXIDE/KAOLIN COMPOSITE HEMOSTATIC ANTIBACTERIAL MATERIAL, HEMOSTATIC HEALING-PROMOTING DRESSING AND PREPARATION METHOD THEREOFDecember 2019February 2022Abandon2621NoNo
16698063ISOTRETINOIN ORAL-MUCOSAL FORMULATIONS AND METHODS FOR USING SAMENovember 2019August 2020Allow910YesNo
16685440FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTSNovember 2019March 2021Abandon1601NoNo
16683963MAGNETIC LIQUID PARTICLESNovember 2019April 2024Abandon5341YesNo
16611149NON-FIBROTIC BIOCOMPATIBLE ELECTRODE AND RELATED METHODSNovember 2019May 2025Abandon6041YesNo
16653883REACTIONS TRIGGERED BY COOLING-INDUCED GEL-TO-SOL TRANSITION OF THERMORESPONSIVE POLYMERSOctober 2019April 2025Abandon6061YesNo
16600233RESPONSIVE COATINGS FOR HAIR FIBERSOctober 2019November 2022Allow3731YesNo
16500513BODY COSMETICOctober 2019December 2022Abandon3831YesNo
16552469MULTI-LAYER CLEANING AND DISINFECTING WIPES HAVING OPTIMAL DELAMINATION BEHAVIOR WITH CLEANING LOTIONAugust 2019April 2023Abandon4441NoNo
16487519SKIN COSMETICAugust 2019August 2021Abandon2411NoNo
16480429SOLID WATER-IN-OIL COSMETIC EMULSIONJuly 2019October 2020Abandon1501NoNo
16476109ULTRAVIOLET-SHIELDING PARTICLE COATED WITH SILICON OXIDE, AQUEOUS COMPOSITION CONTAINING ULTRAVIOLET-SHIELDING PARTICLE COATED WITH SILICON OXIDE, AND COSMETICJuly 2019August 2021Allow2521YesNo
16456601IMPLANTABLE DEVICE FOR THE DELIVERY OF OCTREOTIDE AND METHODS OF USE THEREOFJune 2019March 2021Abandon2110NoNo
16474273COSMETIC COMPOSITION WITH UNIVERSAL OPTICAL CORRECTIONJune 2019February 2024Abandon5641YesYes
16474049CERIA NANOCOMPOSITE FOR BIOMEDICAL TREATMENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAMEJune 2019November 2021Allow2921YesNo
16449856Production Process For Nsaid-Containing Lozenges, Their Compositions, Their Medicinal UseJune 2019October 2020Allow1601YesNo
16471793SOLID COSMETIC COMPOSITION COMPRISING A SILICONE POLYAMIDE, A SILICONE RESIN AND A DISPERSED AQUEOUS PHASEJune 2019July 2023Allow4951YesNo
16441844COMPOSITION, ARTIFICIAL NAIL COMPOSITION, NAIL DECORATION MATERIAL, ARTIFICIAL NAIL, STORED CONTAINER, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHODJune 2019September 2022Allow3941YesNo
16470188A MEDICAL IMPLANT AND A METHOD OF COATING A MEDICAL IMPLANTJune 2019June 2021Abandon2411NoNo
16468023TEXTURED COMPOSITIONSJune 2019September 2021Abandon2721NoNo
16427604METHOD FOR COATING IMPLANT WITH ACTIVE PHARMACEUTICAL INGREDIENTSMay 2019December 2020Abandon1911NoNo
16408903METHOD FOR DELIVERY OF BIOLOGIC AGENTS FROM A TOPICAL FORMULATIONMay 2019June 2021Abandon2611NoNo
16342043SKIN COSMETICSApril 2019July 2021Abandon2721YesNo
16338003METHOD OF TREATING A MATERIAL WITH AN AMINE SALT OF A CARBOXYLIC ACIDMarch 2019December 2022Abandon4541NoNo
16337540METHODS, COMPOSITIONS AND USES RELATING THERETOMarch 2019November 2021Allow3121YesNo
16337459METHODS, COMPOSITIONS AND USES RELATING THERETOMarch 2019August 2022Abandon4041YesNo
16337248FILM-FORMING COMPOSITION FOR SKIN OR HAIR COATINGMarch 2019February 2022Abandon3531NoNo
16337222METHODS, COMPOSITIONS AND USES RELATING THERETOMarch 2019May 2022Allow3832YesNo
16356393Topical Phospholipid Formulations and Methods for Preparing the SameMarch 2019December 2023Abandon5761NoNo
16288488CLEANSING AND CONDITIONING COMPOSITION FOR KERATIN FIBERS, METHOD, USE, AND KIT-OF-PARTS THEREOFFebruary 2019April 2021Abandon2521YesNo
16285883APERTURED HYDROGEL COMPOSITIONS AND WOUND DRESSINGSFebruary 2019April 2022Abandon3731NoNo
16282593ANTIBIOTIC COATINGFebruary 2019January 2021Abandon2221NoNo
16273183CONSUMER PRODUCT COMPOSITIONS COMPRISING MICROCAPSULESFebruary 2019November 2020Abandon2111NoNo
16321373COSMETIC PRODUCT FOR THE LIPS IN THE FORM OF A WATER-IN-OIL EMULSION AND MAKEUP METHODJanuary 2019November 2024Abandon6061NoNo
16308756ABSORBENT ALIPHATIC POLYURETHANE FOAM PRODUCTDecember 2018February 2023Allow5041YesNo
16213630COMPOSITIONS I - I AND PRODUCTS AND USES THEREOFDecember 2018January 2021Abandon2511YesNo
16190893MICROSPHERICAL PARTICLENovember 2018January 2022Abandon3831NoNo
16300116TRANSDERMAL FORMULATIONS FOR DELIVERY OF CELECOXIB AND ITS USE IN THE TREATMENT OF CELECOXIB-RESPONSIVE DISEASES AND CONDITIONSNovember 2018September 2020Abandon2211NoNo
16300513COMPOSITIONS COMPRISING POLYESTERS OF BIOLOGICAL ORIGIN AND BIOCOMPATIBLE INORGANIC COMPOUNDS, AND USES THEREOF IN THE COSMETIC FIELDNovember 2018December 2023Abandon6041NoYes
16165033COMPACT AEROSOL HAIR CARE COMPOSITION COMPRISING HYDROCARBON FOAMING AGENTOctober 2018November 2021Abandon3731YesNo
16165044COMPACT AEROSOL HAIR CARE COMPOSITION COMPRISING HYDROCARBON FOAMING AGENTOctober 2018July 2023Abandon5761YesNo
16159819ANTI-MICROBIAL COMPOSITIONS, PREPARATIONS, METHODS, AND USESOctober 2018July 2020Abandon2110NoNo
16089013IMPROVEMENTS IN STENTS FOR THE RELEASE OF ACTIVE PRINCIPLESSeptember 2018June 2022Abandon4441NoNo
16139363TOPICAL COMPOSITION AND METHOD FOR TREATING AND PREVENTING ATOPIC DERMATITIS AND INFECTIONS RELATED TO BACTERIA BIOFILMSeptember 2018September 2021Allow3631YesNo
16136377ENTERIC COATED TABLETSeptember 2018March 2021Abandon3021NoNo
16131063SUTURABLE WOVEN IMPLANTS FROM ELECTROSPUN YARNS FOR SUSTAINED DRUG RELEASE IN BODY CAVITIESSeptember 2018August 2023Abandon5961YesNo
16083794PARTIALLY DEGRADABLE STENTS FOR CONTROLLED REDUCTION OF INTRAOCULAR PRESSURESeptember 2018January 2025Abandon6081YesNo
16110156ABUSE DETERRENT SOFT CHEWABLE DRUG FORMULATIONSAugust 2018January 2021Abandon2821NoNo
16108886Dietary Supplementation with Mixed Alkali SaltsAugust 2018February 2021Allow3031YesNo
16106930MEDICAL BALLOONS WITH NANOPLATELET COMPOSITE MATERIALS AND METHOD OF MAKING THE SAMEAugust 2018October 2020Abandon2521NoNo
16074993AQUEOUS EMULSION POLYMERS AS RHEOLOGY MODIFIERS, COMPOSITIONS THEREOF, AND METHOD OF USEAugust 2018January 2021Abandon3021NoNo
16072593TENSING AND/OR FILM-FORMING COSMETIC AGENT CONSISTING OF GALACTOMANNANS AND CROSS-LINKED SULPHATED GALACTANSJuly 2018July 2023Allow6051YesNo
16039630DRY BIOCELLULOSE MATERIAL AND PREPARATION THEREOFJuly 2018January 2020Abandon1811NoNo
16030209CONTROLLED RELEASE NUTRIENTS BY COATINGJuly 2018January 2023Abandon5531NoNo
16015806COSMETIC COMPOSITION COMPRISING AT LEAST ONE LAMBDA-CARRAGEENAN POLYSACCHARIDE IN COMBINATION WITH AT LEAST ONE SPECIFIC POLYOL, AND PROCESS FOR COSMETIC TREATMENT OF KERATIN FIBERS WITH THE COMPOSITION, AND USE OF THE COMPOSITION FOR HAIR CAREJune 2018June 2019Abandon1201NoNo
16065143HYDROPHOBICALLY MODIFIED ALKALI-SWELLABLE EMULSION POLYMERSJune 2018January 2021Abandon3021NoNo
16064753SALICYLIC ACID DERIVATIVE, METHOD FOR PREPARING SAME, AND COSMETIC COMPOSITION FOR WHITENING COMPRISING SAMEJune 2018October 2020Abandon2831NoNo
16010898Pre-Mixed, Ready-To-Use Pharmaceutical CompositionsJune 2018April 2020Allow2221YesNo
15781708SOFT GELATIN CAPSULES WITH pH-INDEPENDENT RELEASEJune 2018December 2021Allow4251YesNo
15781913NANOPARTICLE-AQUEOUS DISPERSION LIQUID OF GLYCOSPHINGOLIPIDJune 2018December 2019Abandon1801NoNo
15993020POLYMERIC MESH WITH SELECTIVE PERMEABILITY, FOR THE REPAIR AND REGENERATION OF TISSUESMay 2018March 2021Abandon3440NoNo
15992506Delivery ParticlesMay 2018August 2020Abandon2721NoNo
15780114A HAIR CARE COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOFMay 2018November 2021Abandon4121NoNo
15779898A HAIR CARE COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOFMay 2018October 2019Abandon1711NoNo
15779840ANTI-UV EMULSIONS STABILIZED WITH LIGNIN AND NANOPARTICLESMay 2018November 2021Abandon4241NoNo
15986951STACKED BODY AND SHEET FOR APPLICATION TO SKINMay 2018February 2020Abandon2121YesNo
15986906FIBER ASSEMBLY AND METHOD FOR MANUFACTURING THE SAMEMay 2018February 2020Abandon2121YesNo
15766523FILM FORMING AGENT, AND COSMETIC COMPOSITION AND COSMETIC USING SAMEApril 2018January 2022Abandon4641YesNo
15939045IMPLANTABLE DEVICES FOR TREATING HIVMarch 2018March 2022Abandon4842YesNo
15760534ALCOHOL-BASED SKIN SANITIZER HAVING MICROBICIDAL PROPERTIESMarch 2018August 2021Abandon4231NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BECKHARDT, LYNDSEY MARIE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
27
Examiner Affirmed
22
(81.5%)
Examiner Reversed
5
(18.5%)
Reversal Percentile
30.8%
Lower than average

What This Means

With a 18.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
83
Allowed After Appeal Filing
15
(18.1%)
Not Allowed After Appeal Filing
68
(81.9%)
Filing Benefit Percentile
23.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BECKHARDT, LYNDSEY MARIE - Prosecution Strategy Guide

Executive Summary

Examiner BECKHARDT, LYNDSEY MARIE works in Art Unit 1613 and has examined 498 patent applications in our dataset. With an allowance rate of 28.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner BECKHARDT, LYNDSEY MARIE's allowance rate of 28.1% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BECKHARDT, LYNDSEY MARIE receive 2.80 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BECKHARDT, LYNDSEY MARIE is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +49.6% benefit to allowance rate for applications examined by BECKHARDT, LYNDSEY MARIE. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.6% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.6% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 20.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 51.8% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 44.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.6% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.